The NY Times reports that a federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property.
U.S. Judge Invalidates Human Gene Patent
2 Comments
Recent Posts
AI for All, Details to Follow: Government Releases a Big-Spending AI Strategy That Is Still Short on the Specifics That Matter 
New Privacy Rights in the Morning, Mandatory Metadata Retention in the Afternoon: How Bill C-22 Undercuts the AI Strategy Before It Launches 
From Making Web Giants Pay to Making Taxpayers Pay: Government Announces Plan to Kill the CRTC’s Online Streaming Ruling 
Digital Self-Sabotage: Why Canada’s AI Strategy Is Set to Fail Before it Even Launches 
Why Mark Carney’s Antisemitism Speech Did Not Meet the Moment
“Myriad Genetics, the company that holds the patents with the University of Utah Research Foundation, asked the court to dismiss the case, claiming that the work of isolating the DNA from the body transforms it and makes it patentable. ”
So, they claim they aren’t actually patenting the two genes, they are patenting transformed version of the genes? To me this would invalidate the work of the human genome project, as they cataloged not the human genome but some variation thereof… Or am I understanding the claim incorrectly?
They’re claiming that isolated DNA is “transformed”, so the not-found-in-nature requirement of a patent doesn’t apply to the genes.